AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
AIM - AIM ImmunoTech Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Stock News
AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen's previously published antiviral research
The Hour-Long Project We Never Would've Started
By Andrew Rice, Partner and Portfolio Manager We may often come off as skeptical about AI in our newsletter. Our skepticism is primarily centered on the AI capital spend and AI company valuations rather than the AI tools themselves, which we have found both useful and exciting.
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola
Creo Medical Group to raise £5.5m and advance partial divestment
Creo Medical Group PLC (AIM:CREO, FRA:1RC, OTC:CMEOF) announced plans to raise approximately £5.5 million through a placing as the medical device company moves to strengthen its balance sheet while pursuing the sale of its remaining stake in Creo Medical Europe. The AIM-listed group said it intends to issue around 36.7 million new shares at 15p each, a 31.9% premium to Thursday's closing mid-market price of 11.4p.
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla. , May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company", today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc . (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE Rules of an aggregate of 7,519,351 shares of common stock, par value $0.001 per share (the “Common Stock”) (or common stock equivalents in lieu thereof) at a purchase price of $0.325 per share. The gross proceeds to the Company from the offering are expected to be approximately $2.4 million, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, the Company will issue and sell unregistered Series I warrants (the “Series I Warrants”) to purchase up to 15,038,702 shares of Common Stock. The Series I Warrants will have an exercise price of $0.325 per share, will be exercisable subject to stockholder approval and will expire five (5) years from the initial exercise date.
88 Energy says Augusta-1 exploration well is on track for Q1 2027
88 Energy Ltd (AIM:88E, ASX:88E, OTCQB:EEENF, FRA:POQ) has told investors that its planned Augusta-1 exploration well at South Prudhoe on Alaska's North Slope remains on track for a first-quarter 2027 spud, as the company advances permitting, logistics and farm-out discussions. The AIM and ASX-listed explorer said Augusta-1 is designed to test up to 133.7 million barrels of gross unrisked 2U prospective resources, or 111.4 million barrels net to 88 Energy, across stacked Ivishak, Kuparuk and Brookian reservoir targets.
CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework
SCHAUMBURG, Ill.--(BUSINESS WIRE)-- #isaca--CMMI Institute, a global leader in helping organizations reduce risk, boost performance, and build capability, is now extending this guidance to artificial intelligence, and has recently completed a pilot program for its new AI Maturity (AIM) framework. AIM enables organizations to assess, benchmark and improve how AI is implemented across real-world enterprise and regulatory environments, linking AI practices and governance to measurable, scalable outcomes. T.
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy Increase in stockholder equity and note extension strengthen Company's ability to advance pancreatic cancer development strategy
Europa Oil & Gas drops as North Yorkshire refuses planning for potential gas drilling
Europa Oil & Gas (Holdings) Plc (AIM:EOG, FRA:EGN) shares fell 8.3% to 1.33p after North Yorkshire Council refused planning permission for the Cloughton gas appraisal well in North Yorkshire. The AIM-listed oil and gas group said the decision went against the recommendation of the council's own planning officers, who had advised the local planning authority to approve the application following reviews by 13 independent experts.
Sintana Energy raises $11.5m to support exploration plans in Namibia
Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF, FRA:3ZX1, AIM:SEI) has conditionally raised US$11.5 million to back a busy exploration programme, including drilling on the Chevron-operated Nabba-1 well in Namibia's PEL 90. The fundraise was priced at 22.5p per new common share on AIM and C$0.41 on the TSX-V, with the company set to issue 38.0 million new shares.
CelLBxHealth strikes US clinical collaboration with AdventHealth cancer studies
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed circulating tumour cell (CTC) diagnostics company, has secured a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, to deploy its Parsortix platform in two clinical cancer studies. The trials, titled ACTION and SUNRISE, will use CelLBxHealth's technology to isolate and analyse CTCs from blood samples taken from patients undergoing treatment for colon, gastrointestinal and lung cancers.
Union Jack Oil says Crossroads well drilled on-budget, production testing due to start in June
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) told investors that its Crossroads well in Garvin County, Oklahoma, has been drilled on budget to a target depth of 4,600 feet, with evaluation and testing scheduled to begin in mid-June. The AIM-listed onshore hydrocarbons company, which has a 43% interest in the well, said electric logs have been acquired and several zones of interest and test intervals identified.
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consultant for AIM ImmunoTech, is now available on demand here OCALA, Fla.
OptiBiotix shares surge 13.5% as company plans SweetBiotix showcase for investors
OptiBiotix Health PLC (AIM:OPTI, OTCQB:OPTBF), the AIM-listed life sciences company developing gut microbiome products and healthy sugar substitutes, saw its shares jump 13.5% to 5.68p after announcing plans to demonstrate its SweetBiotix products to shareholders at a London event in June. The company reported a breakthrough in the manufacture of SweetBiotix in November 2025, achieving higher yields of a purer, more concentrated and better-tasting product with lower ingredient and production costs.
Aimia Inc. (AIM:CA) Shareholder/Analyst Call Transcript
Aimia Inc. (AIM:CA) Shareholder/Analyst Call Transcript
Candor Technology Integrates with Freddie Mac's AIM Check API to Automate Income Calculations
ALPHARETTA, Ga., May 13, 2026 (GLOBE NEWSWIRE) -- Candor Technology, Inc., a leader in AI-driven mortgage decisioning, is now integrated with Freddie Mac's AIM Check API, enabling automated income calculation for W-2 borrowers directly through Candor's patented Loan Engineering System (LES).
Aimia Inc. (AIM:CA) Q1 2026 Earnings Call Transcript
Aimia Inc. (AIM:CA) Q1 2026 Earnings Call Transcript